Supplementary Appendix
|
|
- Erin McCarthy
- 6 years ago
- Views:
Transcription
1 Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011;365:430-8.
2 Supplementary Appendix Supplemental Figure 1. Schematic representation of the original study design. Schematic representation of the original study design. The original design included randomization among horse anti-thymocyte globulin (ATG) plus cyclosporine, rabbit ATG plus cyclosporine, and alemtuzumab. Horse ATG was administered at 40 mg/kg/day for 4 days, rabbit ATG at 3.5 mg/kg/day for 5 days, and alemtuzumab 10 mg/day for 10 days. After 16 patients were randomized to alemtuzumab, accrual to this arm was discontinued at the recommendation of the Data Safety and Monitoring Board due to low response rate and early deaths in this group. The study continued as 1:1 randomization between horse and rabbit ATG. Details of treatment-naïve patients who received alemtuzumab as well as the efficacy of alemtuzumab in relapsed and refractory severe aplastic anemia will be reported separately. The primary endpoint was hematologic response assessed at 6 months. Responders in all groups were evaluated long-term for secondary endpoints. Non-responders in the horse ATG arm went off study. In the rabbit ATG arm, non-responders were allowed to cross-over to the alemtuzumab arm, while non-responders in the initial alemtuzumab arm allowed to cross-over to the rabbit ATG group. 1
3 Supplemental Figure 2. Enrollment, randomization, and treatment through 6 months. Enrollment, randomization, and treatment through 6 months. All consecutive patients who met eligibility criteria enrolled into the study. There was an early evolution to leukemia in one patient treated with horse ATG prior to the 3 months and the patient underwent a matched sibling stem cell transplantation. In the rabbit ATG arm, 3 patients died prior to the 3-month evaluation time point: 2 from infectious complications (polymicrobial sepsis (1) and necrotizing fasciitis (1)) and one from intracranial hemorrhage shortly after initiating rabbit ATG administration. Between 3 and 6 months, one patient in the horse ATG arm and 6 in the rabbit ATG arm went off study due to rapid clinical deterioration, recurrent life-threatening systemic infections not adequately controlled with antimicrobials, and progressive pancytopenia. In the horse ATG group, the patient received second line immunosuppression, and in the rabbit ATG group, 2 received second line immunosuppression and 4 underwent emergent stem cell transplantation (3 from a histocompatible sibling and one from a matched unrelated donor). In total, 58 patients in the horse ATG and 51 in the rabbit ATG arm were evaluable for hematologic response at 6 months (primary endpoint). Analysis was intention-to-treat and patients who died or went off study prior to 6 months were counted as non-responders for the primary endpoint (see Methods, Statistical Analysis). 2
4 Supplemental Figure 3. Disposition among non-responders at 6 months to immunosuppression. Disposition among non-responders at 6 months to immunosuppression. Among the 17 nonresponders to horse ATG, 5 underwent stem cell transplantation, 4 from a histocompatible sibling and one from a matched unrelated donor. Eight patients underwent second line immunosuppression (rabbit ATG plus cyclosporine or alemtuzumab). Of the 29 non-responders in the rabbit ATG group, 23 received second line immunosuppression (horse ATG plus cyclosporine or alemtuzumab). Four patients underwent stem cell transplantation, 3 from a histocompatible sibling and one from an unrelated donor. Six patients who did not respond to second line immunosuppression went on to receive a stem cell transplantation, one from a histocompatible sibling, 4 from an unrelated donor, and one received a haploidentical/umbilical cord transplant. 3
5 Supplemental Figure 4. Late events after immunosuppressive therapy. Late events after immunosuppressive therapy. (A) Cumulative incidence of hematologic relapse (among responders). The effectiveness of continued cyclosporine cannot be determined in the current study due to the relative short follow-up among the responders to horse ATG. (B) Cumulative incidence of clonal evolution (all patients). Numbers at the bottom of each graph indicate patients at risk for each time point. 4
6 Supplemental Methods Study patients For protocol entry purposes, severe aplastic anemia was defined as bone marrow cellularity less than 30% and severe pancytopenia by at least two of the following peripheral blood count criteria: 1) absolute neutrophil count < 500 /µl; 2) absolute reticulocyte count < 60,000 /µl; and 3) platelet count < 20,000 /µl. 1 For children and young adults (< 40 years of age) chromosomes were assayed after in vitro exposure of lymphocytes to diepoxybutane and to mitomycin C to exclude Fanconi anemia. Patients with a clonal hematologic disorder as inferred from bone marrow cytogenetics or characteristic morphologic changes on bone marrow were excluded. All patients were tested for paroxysmal nocturnal hemoglobinuria by flow cytometry. 2 Immunosuppressive regimens Among responders in the horse ATG arm, cyclosporine was tapered starting at 6 months over subsequent 18 months and in the rabbit ATG arm, cyclosporine was discontinued at 6 months. (At our institution it is standard practice to discontinue cyclosporine at 6 months, but since 2003, all responders to horse ATG have had the cyclosporine dose tapered to determine its effectiveness in preventing relapse.) Prophylaxis for Pneumocystis carinii was with aerosolized pentamidine monthly and for Herpes simplex, valacyclovir daily. 5
7 Flow cytometric analysis After thawing, cells were washed, counted, and resuspended in phosphate buffered saline (PBS). Viability staining was performed for 30 min in presence of LIVE/DEAD Aqua fixable viability dye (Life Sciences, Carlsbad, CA) followed by washing in staining buffer (PBS supplemented with 1% normal mouse serum, 1% goat serum and 0.02% sodium azide; Gemini Bioproducts, West Sacramento, CA). Cell membranes were then stained at room temperature for 30 minutes with the following directly conjugated monoclonal antibodies: anti-cd45 quantum dot (QD) 800 (Life Sciences), anti-cd3 APC-H7 (BD Biosciences), anti-cd4 v450 (BD Biosciences), anti-cd8 QD 605 (Life Sciences), anti-cd 127 Alexa 647 (BD Biosciences), and anti-cd25 PE-Cy7 (BD Biosciences) was performed for 30 min in the dark at room temperature. Cells were then washed three times with FACS staining buffer and were acquired the same day. Data were acquired on a Becton Dickinson LSR II equipped with four lasers (407 nm, 488 nm, 532 nm, and 633 nm wavelengths) with 18 PMT detectors, optimized as previously described. 3 Data were acquired using DIVA software (BD, San Jose, CA) and the analysis was performed using Flowjo 9.3 (Treestar Inc., San Carlos, CA). For the analysis, lymphocytes were identified based on their forward and side scatter properties. Subsequently, dead cells were excluded through the use of an aqua viability dye. T cells were identified by expression of CD3 and CD45 among previously selected viable lymphocytes. For this analysis, regulatory T cells were identified as CD4 + CD25 + CD127 - as previously reported. 4 6
8 Statistical Methods The response rates between the two treatment arms were calculated and compared using the two-sample T-test for proportions. Patient characteristics were described using summary statistics including means, proportions, standard errors and 95% confidence intervals. P-values for comparing these patient characteristics between the two treatment groups were calculated using T-tests. Kaplan-Meier and the Cox proportional hazard models were used to compare overall survival (all patients), time-to-relapse (among responders) and time-to-evolution (all patients) between the two therapies. Log-rank p- values based on the Cox proportional hazard models were used to compare the survival and cumulative event curves between the two treatments. For response analysis, patients who were not evaluable at 6 months due to death or the need to pursue alternative therapies secondary to significant clinical deterioration were counted as non-responders. For the analyses of time-to-relapse and time-to-evolution distributions, patients who died or underwent stem cell transplant before these events were counted as censored. Based on the O Brien-Fleming spending function with one interim analysis, a P-value < was considered statistically significant for the final analysis of the primary endpoint. A P- value of < 0.05 was considered statistically significant for all secondary endpoints. Analysis was intention to treat and conducted after the last patient became evaluable for the primary endpoint in January 10, The numerical results were computed with S- PLUS 8.0 statistical package (TIBCO Software Inc, Palo Alto, CA). For the flow cytometric data, a paired t-test was used to determine significance of differences between populations at each time point (GraphPad Prism version 5, San Diego, CA). 7
9 Supplemental Table 1. Summary of serious adverse events Related to immunosuppression Event Horse ATG Rabbit ATG Serum sickness 2 5 Chest pain 1 0 Hemolysis a 0 1 SVT 0 1 Azotemia 1 0 PRES 0 1 Hemorrhage CNS 0 1 Vitreous 0 1 Hematemesis 0 1 Epistaxis 1 1 Menorrhagia 2 0 Hemoptysis 1 0 Infection Neutropenic fever, negative cultures Neutropenic fever, positive cultures Polymicrobial b 0 6 Pneumonia c 1 3 Necrotizing fasciitis d 0 1 Clostridium difficile 2 2 Retropharyngeal abscess 0 1 Peri-rectal abscess 0 1 Peri-orbital cellulitis 1 0 Tonsillitis/pharyngitis 2 1 Apendicitis/typhlitis 0 4 Otitis media 1 0 Epididymitis 0 1 Upper respiratory infection 5 e 1 Other 9 11 Serious adverse events depicted are those that resulted in prolonged hospitalization, hospital admission or death. Events shown are those that occurred after the first cycle of immunosuppression. Repeated hospitalizations in the 8
10 same subject were counted as separate events. PRES, posterior reversible encephalopathy syndrome; SVT, supraventricular tachycardia; CNS, central nervous system. a Hemolysis occurred after ATG infusion in a patient with a large underlying paroxysmal nocturnal hemoglobinuria clone b Patients with multiple microbial isolates and/or different sites of infection are categorized as having polymicrobial infection. The organisms recovered and sites for each of the patients were: 1) Escherichia coli, Staphylococcus epidermidis, Enterococcus faecium, Acinetobacter baumanii (all in blood); Enterococcus sp., Staphylococcus sp, and mold (left turbinate biopsy); 2) Pseudomonas sp, Klebsiella sp, Staphylococcus epidermidis, Streptococcus viridans, Staphylococcus hemolyticus, Enterococcus faecium, and Stenotrophomonas maltophilia (all in blood); 3) Enterobacter cloacae, Pseudomonas aeruginosa (respiratory cultures); Acinetobacter baumanii, Mycobacterium gordonae, Fusarium sp, Acinetobacter baumanii, Enterococcus faecalis (sinus culture), Corynebacterium sp (blood), Proteus mirabilis (urine); 4) Propionibacterium acnes, Staphylococcus aureus, Candida albicans (throat); 5) Streptococcus sp (blood), Trichosporon asahii (sinus), Candida albicans (skin); 6) Enterococcus faecium, Staphylococcus epidermidis (blood), Klebsiella pneumoniae (urine). c One case of fungal pneumonia in each group d Caused by Clostridium sp e In 3 subjects viral infection was confirmed by nasopharyngeal wash. References for Supplemental Appendix 1. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long- term outcome. JAMA 2003;289: Scheinberg P, Marte M, Nunez O, Young NS. Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti- thymocyte globulin plus cyclosporine. Haematologica 2010;95: Perfetto SP, Ambrozak D, Nguyen R, Chattopadhyay P, Roederer M. Quality assurance for polychromatic flow cytometry. Nat Protoc 2006;1: Banham AH. Cell- surface IL- 7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells. Trends Immunol 2006;27:
The function of the bone marrow. Living with Aplastic Anemia. A Case Study - I. Hypocellular bone marrow failure 5/14/2018
The function of the bone marrow Larry D. Cripe, MD Indiana University Simon Cancer Center Bone Marrow Stem Cells Mature into Blood Cells Mature Blood Cells and Health Type Function Term Red Cells Carry
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the author to give readers additional information about his work. Supplement to: Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved
More informationAplastic Anemia. is a bone marrow failure disease 9/19/2017. What you need to know about. The 4 major components of blood
What you need to know about Aplastic Anemia Stuart Goldberg MD Aplastic Anemia is a bone marrow failure disease The bone marrow is the factory that makes blood The 4 major components of blood Red Blood
More informationParoxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine
Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine Phillip Scheinberg, Michael Marte, Olga Nunez, and Neal S. Young
More informationShould we still use Camitta s criteria for severe aplastic anemia?
VOLUME 47 ㆍ NUMBER 2 ㆍ June 2012 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Should we still use Camitta s criteria for severe aplastic anemia? Hyun Hwa Yoon, Seok Jae Huh, Ji Hyun Lee, Suee Lee,
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for
More informationAplastic Anemia: Understanding your Disease and Treatment Options
Aplastic Anemia: Understanding your Disease and Treatment Options No financial relationships or commercial interest related to the content of this presentation Josh Sasine, MD, PhD Hematopoietic Cell Transplant
More informationOverview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017
Overview of Aplastic Anemia Overview of Aplastic Anemia Peter Westervelt, MD, PhD Professor of Medicine Chief, BMT/Leukemia Section Washington University School of Medicine Epidemiology Normal hematopoiesis
More informationImproved prognosis for acquired aplastic anaemia
158 Department of Haematology and Oncology, Great Ormond Street Hospital for Children NHS Trust, London WC1N 3JH, UK L A Pitcher I M Hann JPMEvans P Veys J M Chessells DKHWebb Correspondence to: Dr Webb.
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationOutline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options
Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options Carlos M. de Castro, MD Duke University Medical Center Outline What is Aplastic Anemia? What other diseases
More informationHorse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia
The new england journal of medicine original article Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia Phillip Scheinberg, M.D., Olga Nunez, R.N., B.S.N., Barbara Weinstein, R.N.,
More informationHow I treat acquired aplastic anemia
How I treat acquired aplastic anemia Phillip Scheinberg and Neal S. Young Blood Volume 120(6):1185-1196 August 9, 2012 2012 by American Society of Hematology Symptoms, Signs, and Lab Findings Bruising,
More informationIN PATIENTS WITH APLASTIC ANEMIA,
ORIGINAL CONTRIBUTION Antithymocyte Globulin and Cyclosporine for Severe Aplastic Anemia Association Between Hematologic Response and Long-term Outcome Stephen Rosenfeld, MD Dean Follmann, PhD Olga Nunez,
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationCynthia Fata, MD, MSPH 6/23/15
Cynthia Fata, MD, MSPH 6/23/15 Clinical case presentation Introduction to thrombopoietin Development of thrombopoietic agents Clinical Indications Eltrombopag use in aplastic anemia Future uses 33 yo F
More informationSUPPLEMENTARY MATERIAL
SUPPLEMENTARY MATERIAL (A) Further inclusion criteria and categorisation of ICD-10 diagnostic codes Pneumonia: A310 Pulmonary mycobacterial infection A420 Pulmonary actinomycosis A481 Legionnaires' disease
More information9/9/2015 HISTORY & EPIDEMIOLOGY. Objectives. Textbook Definition of Aplastic anemia (AA) Epidemiology. History
Objectives Aplastic Anemia: Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Amy E. DeZern, MD, MHS Assistant Professor of Oncology and Medicine The Johns Hopkins University School
More information3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)
3 Results 3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) Five infusions of monoclonal IL-2 receptor antibody (anti-cd25) were planned according to protocol between day 0 and day
More informationBor-Sheng Ko. Hematology Division, Department of Internal Medicine, National Taiwan University Hospital
Bor-Sheng Ko Hematology Division, Department of Internal Medicine, National Taiwan University Hospital On behalf of Members of Aplastic Anemia Consensus Meeting Diagnosis and classification: Treatment
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationAtgam (lymphocyte immune globulin, anti-thymocyte globulin [equine])
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.20.01 Subject: Atgam Page: 1 of 5 Last Review Date: June 24, 2016 Atgam Description Atgam (lymphocyte
More informationShall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD
Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD Declaração de Conflito de Interesse Declaro que possuo conflito de
More informationLate Complications Following Treatment for Severe Aplastic Anemia (SAA) with High-Dose Cyclophosphamide (Cy): Follow up of a Randomized Trial
Blood First Edition Paper, prepublished online June 28, 2002; DOI 10.1182/blood-2002-02-0494 Late Complications Following Treatment for Severe Aplastic Anemia (SAA) with High-Dose Cyclophosphamide (Cy):
More informationLiving with PNH 7/3/2013. Paroxysmal Nocturnal Hemoglobinuria (PNH): A Chronic, Systemic, and Life- Threatening Disease
Living with PNH Laurence A. Boxer, MD University of Michigan Case Study 15 year old awakened in the morning with chest pain and a sore throat. She experienced chest pain all day accompanied with coughing
More informationDisorders of immune system in hematology Stomatologic complications of treatment in hematology. Semminar for students E.Faber
Disorders of immune system in hematology Stomatologic complications of treatment in hematology Semminar for students E.Faber Topics Disorders of immune system in hematology Principles of treatment in hematology
More informationAplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment
7/23/212 Aplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment Danielle Townsley, MD, MSc Hematology Branch National, Heart, Lung and Blood Institute National Institutes
More informationAplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment
4/18/212 Aplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment Bogdan Dumitriu, MD Hematology Branch National, Heart, Lung and Blood Institute National Institutes of Health
More information3/31/2014. New Directions in Aplastic Anemia Treatment: What s on the Horizon? Objectives
New Directions in Aplastic Anemia Treatment: What s on the Horizon? AA & MDS International Foundation Living with, MDS, or PNH Patient and Family Conferences in 2014 April 5, 2014 Objectives To provide
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in
More informationQ 1 (May-July 2016) Q 2 (August-October 2016) Q 3 (November 2016-January 2017)
Adult ICU: May 2016-July 2017 Table 1a. Counts and rates of positive blood cultures and blood stream infections which meet the case definition in your critical care unit and for all adult critical care
More informationImmunosuppressive treatment in acquired aplastic anemia. André Tichelli Hematology, University Hospital Basel
Immunosuppressive treatment in acquired aplastic anemia André Tichelli Hematology, University Hospital Basel Why is immunosuppressive treatment a choice for acquired aplastic anemia? Hematopoietic stem
More informationAplastic Anemia Pathophysiology and Approach to Therapy
Aplastic Anemia Pathophysiology and Approach to Therapy BSMCON 2018 Dr. Syed Ghulam Mogni Mowla MBBS, FCPS, FACP Introduction Aplastic anaemia (AA) is the paradigm of the human bone marrow failure syndromes
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Promacta (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationImmunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC Experience
36 supplement to Journal of the association of physicians of india Published on 1st of every month 1st march, 2015 Immunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC
More informationPacientes jovens sem doador com anemia aplástica grave devem receber TMO de fonte alternativa de CTH NO!
Pacientes jovens sem doador com anemia aplástica grave devem receber TMO de fonte alternativa de CTH NO! Phillip Scheinberg, MD Head, Clinical Hematology Hospital A Beneficência Portuguesa de Sao Paulo
More informationSevere Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia
Severe Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia Liat Shragian Alon, MD Rabin Medical Center, ISRAEL #EBMT15 www.ebmt.org Patient: 25-year-old male No prior medical history
More informationThe use of the complement inhibitor eculizumab (Soliris R ) for treating Korean patients with paroxysmal nocturnal hemoglobinuria
VOLUME 45 ㆍ NUMBER 4 ㆍ December 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE The use of the complement inhibitor eculizumab (Soliris R ) for treating Korean patients with paroxysmal nocturnal
More informationPathophysiology 7/18/2012 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA OUTLINE OF DISCUSSION WHAT IS IT WHO GETS IT NATURAL HISTORY TYPES RISKS COURSE TREATMENTS SYMPTOMS PREGNANCY Pathophysiology Acquired hematopoietic stem cell disorder
More informationPearson r = P (one-tailed) = n = 9
8F4-Specific Lysis, % 1 UPN1 UPN3 8 UPN7 6 Pearson r =.69 UPN2 UPN5 P (one-tailed) =.192 4 UPN8 n = 9 2 UPN9 UPN4 UPN6 5 1 15 2 25 8 8F4, % Max MFI Supplementary Figure S1. AML samples UPN1-UPN9 show variable
More informationCHAPTER 2 PROTOCOL DESIGN
CHAPTER 2 PROTOCOL DESIGN CHAPTER 2 PROTOCOL DESIGN 2.1 ELIGIBILITY CRITERIA Participants fulfilling the following criteria will be eligible for enrollment in the protocol: 1. Participant is diagnosed
More informationSummary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016
Page 1 of 8 Date: July 22, 2016 Summary of Changes Page BMT CTN 1205 Protocol #4 Dated July 22, 2016 The following changes, and the rationale for the changes, were made to the attached protocol in this
More informationEx vivo Human Antigen-specific T Cell Proliferation and Degranulation Willemijn Hobo 1, Wieger Norde 1 and Harry Dolstra 2*
Ex vivo Human Antigen-specific T Cell Proliferation and Degranulation Willemijn Hobo 1, Wieger Norde 1 and Harry Dolstra 2* 1 Department of Laboratory Medicine - Laboratory of Hematology, Radboud University
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationProduct: Blinatumomab Clinical Study Report: MT Date: 11 July 2014 Page 1
Date: 11 July 2014 Page 1. 2. SYNOPSIS Name of Sponsor: Amgen Research (Munich) GmbH Name of Finished Name of Active Ingredient: Blinatumomab, a murine recombinant single-chain antibody derivative that
More information2. Does the patient have a diagnosis of chronic idiopathic thrombocytopenic purpura (ITP)?
Pharmacy Prior Authorization MERC CARE (MEDICAID) Promacta (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationHealthcare- Associated Infections: Preventing the Preventable
Healthcare- Associated Infections: Preventing the Preventable HEALTHCARE-ASSOCIATED INFECTIONS: PREVENTING THE PREVENTABLE Course # 516 5 CE Hours Author: Diana Harland, BS, CCRC, Editor: Cheryl Duksta,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy
More informationeltrombopag (Promacta )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization MERC CARE (MEDICAID) Promacta (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationHYPOCHLOROUS ACID (HOCl) Our Body's immune system protector in a BOTTLE
AQUAOX IS A REVOLUTIONARY DISINFECTION SOLUTION WHICH ACTIVE INGREDIENT HOCL IS NON HAZARDOUS, HAS NO FRAGRANCE, AND IS SAFE ON ALL SURFACES (AND ON SKIN.) HYPOCHLOROUS ACID (HOCl) Our Body's immune system
More informationNEONATAL SEPSIS. Dalima Ari Wahono Astrawinata Departemen Patologi Klinik, FKUI-RSCM
NEONATAL SEPSIS Dalima Ari Wahono Astrawinata Departemen Patologi Klinik, FKUI- Background Neonatal sepsis : Early-onset Late-onset Early-onset : mostly premature neonates Within 24 hours 85% 24-48 hours
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 ANTILYMPHOCYTE GLOBULINS FRESENIUS 20 mg/ml, solution to dilute for infusion 10 glass bottle(s) of 5
More informationSupplementary Figure 1. Antibiotic partially rescues mice from sepsis. (ab) BALB/c mice under CLP were treated with antibiotic or PBS.
1 Supplementary Figure 1. Antibiotic partially rescues mice from sepsis. (ab) BALB/c mice under CLP were treated with antibiotic or PBS. (a) Survival curves. WT Sham (n=5), WT CLP or WT CLP antibiotic
More informationACUTE LYMPHOBLASTIC LEUKEMIA
ACUTE LYMPHOBLASTIC LEUKEMIA YOUNG ADULT PATIENT Highlights clonoseq Tracking (MRD) Testing in the peripheral blood revealed early signs of relapse post-transplant Patient achieved remission after CAR-T
More informationFederica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1
Administration of Rivogenlecleucel (Rivo-cel, BPX-501) Following αβ T- and B-Cell Depleted Haplo-HSCT in Children With Transfusion-Dependent Thalassemia Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani,
More informationNot So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology
Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to:
More informationManagement of Catheter Related Bloodstream Infection (CRBSI), including Antibiotic Lock Therapy.
Management of Catheter Related Bloodstream Infection (CRBSI), including Antibiotic Lock Therapy. Written by: Dr K Gajee, Consultant Microbiologist Date: June 2017 Approved by: Drugs & Therapeutics Committee
More informationObjectives. What is Aplastic Anemia. SAA 101: An Introductory Course to Severe Aplastic Anemia
SAA 101: An Introductory Course to Severe Aplastic Anemia David A. Margolis, MD Professor of Pediatrics/Medical College of Wisconsin Program Director/ Children s Hospital of Wisconsin BMT Program Objectives
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationInfection Data: Form Updates
Infection Data: Form Updates Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Why is infection data important?
More informationPEACEHEALTH LABORATORIES
360-414-2306 www.peacehealthlabs.org Critical Values Call List - Longview Critical values are reported per the criteria published below. Laboratory results meeting these criteria indicate potential life-threatening
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationUpdate on THERAFLEX UV-Platelets: a novel system for pathogen reduction of platelets
Update on THERAFLEX UV-Platelets: a novel system for pathogen reduction of platelets Axel Seltsam, MD, MHBA German Red Cross Blood Service NSTOB, Springe Fribourg 2011 THERAFLEX UV-Platelets Efficient
More informationAilyn T. Isais-Agdeppa, MD*, Lulu Bravo, MD*
A FIVE-YEAR RETROSPECTIVE STUDY ON THE COMMON MICROBIAL ISOLATES AND SENSITIVITY PATTERN ON BLOOD CULTURE OF PEDIATRIC CANCER PATIENTS ADMITTED AT THE PHILIPPINE GENERAL HOSPITAL FOR FEBRILE NEUTROPENIA
More informationIMMUVIEW S. PNEUMONIAE ANTIGEN TEST. Lateral flow test for qualitative detection of S. pneumoniae in urine and cerebrospinal fluid.
IMMUVIEW S. PNEUMONIAE ANTIGEN TEST Lateral flow test for qualitative detection of S. pneumoniae in urine and cerebrospinal fluid. 2 IMMUVIEW S. PNEUMONIAE ANTIGEN TEST For in vitro diagnostic use Application
More informationTherapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.
Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific
More informationThis was a multi-center study conducted at 44 study centers. There were 9 centers in the United States and 35 centers in Europe.
Protocol CAM307: A Phase 3 Study to Evaluate the Efficacy and Safety of Frontline Therapy with Alemtuzumab (Campath ) vs Chlorambucil in Patients with Progressive B-Cell Chronic Lymphocytic Leukemia These
More informationCeftizoxime in the treatment of infections in patients with cancer
Journal of Antimicrobial Chemotherapy (98), Suppl. C, 67-73 Ceftizoxime in the treatment of infections in patients with cancer V. Fainstein, R. Bolivar,. Elting, M. Valdivieso and G. P. Bodey Department
More informationAplastic Anemia: Current Thinking
Aplastic Anemia: Current Thinking ANDREW C. DIETZ, MD, MSCR PEDIATRIC BLOOD AND MARROW TRANSPLANTATION CHILDREN S HOSPITAL LOS ANGELES, UNIVERSITY OF SOUTHERN CALIFORNIA Outline Ø What is Aplastic Anemia?
More informationYear 2002 Paper two: Questions supplied by Jo 1
Year 2002 Paper two: Questions supplied by Jo 1 Question 70 A 25 year old previously well male student presents with recent exertional dyspnoea, epistaxis and bruising. There is no history of medication,
More informationWARNING: TENDON EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS
DECLESAU (dergrafloxacin) tablets, for oral use DECLESAU (dergrafloxacin) injection, solution for intravenous use WARNING: TENDON EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS Fluoroquinolones, including
More informationSurveillance of Healthcare Associated Infections in Scottish Intensive Care Units
Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Annual report of data from January 2011 to December 2011 Scottish Intensive Care Society Audit Group Health Protection
More informationHaploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia
Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Carmem Bonfim Director Pediatric Blood and Marrow Transplantation Program HC Federal
More informationSupplementary Information
Supplementary Information Methods Lymphocyte subsets analysis was performed on samples of 7 subjects by flow cytometry on blood samples collected in ethylenediaminetetraacetic acid (EDTA)-containing tubes
More informationKENNEL KARE SC DISINFECTANT / CLEANER / DEODORIZER Efficacy Data EPA Reg. #
Inc. Efficacy: Hospital Disinfection (at ½ ounce per gallon) Kennel Kare SC is bactericidal according to the AOAC Use Dilution Test method on hard inanimate surfaces modified in the presence of 5% organic
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSurveillance of Healthcare Associated Infections in Scottish Intensive Care Units
Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Annual report of data from January 2010 to December 2010 Scottish Intensive Care Society Audit Group 1 Health Protection
More informationINHERITED PANCYTOPENIA SYNDROMES Fanconi anemia Shwachman-Diamond syndrome Dyskeratosis congenita Congenital amegakaryocytic thrombocytopenia
The Pancytopenias The Inherited Pancytopenias Pancytopenia refers to a reduction below normal values of all 3 peripheral blood component: leukocytes, platelets, and erythrocytes. Pancytopenia requires
More informationSevere and Tertiary Peritonitis
Severe and Tertiary Peritonitis Addison K. May, MD FACS Professor of Surgery and Anesthesiology Division of Trauma and Surgical Critical Care Vanderbilt University Medical Center PS204: The Bad Infections:
More informationhematology Board Review Manual
Volume 6, Part 1 april 2011 hematology Board Review Manual Aplastic Anemia: Review Questions Merck is pleased to provide this material as a professional service to the medical community. The Hospital Physician
More informationAntimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association
Antimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association Els Vandecasteele, Jan De Waele, Dominique Vandijck, Stijn Blot, Dirk
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: The National Heart, Lung, and Blood Institute Acute Respiratory
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationLong-term risk of cancer development in adult patients with idiopathic aplastic anemia after treatment with anti-thymocyte globulin
Published Ahead of Print on July 13, 2017, as doi:10.3324/haematol.2017.171215. Copyright 2017 Ferrata Storti Foundation. Long-term risk of cancer development in adult patients with idiopathic aplastic
More informationMicrosan rx Anti-Microbial Healthcare Professional Soap. Organism Positives ATCC #
: Contact Time: 30 seconds 17,500 ppm. PCMX active Organism Positives ATCC # Acinetobacter calcoaceticus var. anitratus 0 s Acinetobacter calcoaceticus var. woffii 0 s Actinobacillus pleuropneumonia 0
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationElias Hallack Atta, 1 Adriana Martins de Sousa, 1 Marcelo Ribeiro Schirmer, 1 Luis Fernando Bouzas, 1 Marcio Nucci, 2 Eliana Abdelhay 1
Different Outcomes between Cyclophosphamide Plus Horse or Rabbit Antithymocyte Globulin for HLA-Identical Sibling Bone Marrow Transplant in Severe Aplastic Anemia Elias Hallack Atta, 1 Adriana Martins
More informationSevere Aplastic Anemia in Children and Adolescents. Brigitte Strahm 21. April 2018
Severe Aplastic Anemia in Children and Adolescents Brigitte Strahm 21. April 2018 Acquired Aplastic Anemia in children What is aquired aplastic anemia? Camitta, Blood 1976 How A.L.G. acts is unknown, but
More informationIn the absence of underlying edema or other skin abnormalities, erysipelas
ERYSIPELAS Erysipelas is a distinct type of superficial cutaneous cellulitis with marked dermal lymphatic vessel involvement caused by group A β-hemolytic streptococcus (very uncommonly group C or G streptococcus)
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib
More informationBlocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-
Supplementary Methods Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- L1 (10F.9G2, rat IgG2b, k), and PD-L2 (3.2, mouse IgG1) have been described (24). Anti-CTLA-4 (clone
More informationNaive, memory and regulatory T lymphocytes populations analysis
Naive, memory and regulatory T lymphocytes populations analysis Jaen Olivier, PhD ojaen@beckmancoulter.com Cellular Analysis application specialist Beckman Coulter France Introduction Flow cytometric analysis
More informationWISKOTT-ALDRICH SYNDROME. An X-linked Primary Immunodeficiency
WISKOTT-ALDRICH SYNDROME An X-linked Primary Immunodeficiency WHAT IS WISKOTT ALDRICH SYNDROME? Wiskott-Aldrich Syndrome (WAS) is a serious medical condition that causes problems both with the immune system
More informationFulviSan-D. Product Applications: *food and beverage process plants, kitchens and serving establishments *live-stock farming: dairy, meat and poultry
FulviSan-D Description: FulviSan-D is a dark brown concentrated liquid detergent, contains pure organic plant acids, designed for surface contact disinfectant requirements in the livestock, food processing
More informationEpidemiology of Infectious Complications of H1N1 Influenza Virus Infection
Epidemiology of Infectious Complications of H1N1 Influenza Virus Infection Lyn Finelli, DrPH, MS Lead, Influenza Surveillance and Outbreak Response Epidemiology and Prevention Branch Influenza Division
More informationHANDS Instant Sanitizing Wipes
HANDS Instant Sanitizing Wipes TECH DATA BULLETIN PRODUCT DESCRIPTION Sani Professional Hands Instant Sanitizing Wipes are nonwoven cloth saturated with an ethyl alcohol solution for the antimicrobial
More information